# Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Source: https://onco.cc/trials/nct06792734/  
OnCo record `nct06792734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BTM-3566 run by Bantam Pharmaceuticals, now recruiting.

## Summary

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas is a phase 1 interventional study registered as NCT06792734 by Bantam Pharmaceuticals, with 24 participants planned, started 2025-02-14. Conditions recorded: Lymphoma, B-Cell. Interventions recorded: BTM-3566.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06792734
- Phase: 1
- Setting: Phase 1A/1B Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
- Sponsor: Bantam Pharmaceuticals
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06792734: https://clinicaltrials.gov/study/NCT06792734

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [BTM-3566](https://onco.cc/drugs/btm-3566/)
- companies: [Bantam Pharmaceutical](https://onco.cc/companies/bantam-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06792734.json